title: Prenatal pharmacotherapy for fetal anomalies: a 2011 update.
abstract: Fetal therapy can be defined as any prenatal treatment administered to the mother with the primary indication to improve perinatal or long-term outcomes for the fetus or newborn. This review provides an update of the pharmacological therapies that are solely directed at the fetus with anomalies and outlines a future transcriptomic approach. Fetal anomalies targeted with prenatal pharmacotherapy are a heterogeneous group of structural, endocrine, and metabolic conditions, including congenital cystic adenomatoid malformation (CCAM), congenital adrenal hyperplasia, congenital heart block, fetal tachyarrhythmias, inborn errors of metabolism, fetal thyroid disorders, and polyhydramnios. To date, the majority of pharmacotherapies for fetal anomalies have been evaluated only in retrospective, uncontrolled studies. The way forward will be with an evidence-based approach to prenatal pharmacological interventions.
authors.affiliation: Mother Infant Research Institute, Tufts Medical Center, Boston, MA, USA. LHui@tuftsmedicalcenter.org
authors.forename: Lisa
authors.initials: L
authors.lastname: Hui
authors.forename: Diana W
authors.initials: DW
authors.lastname: Bianchi
mesh_terms: D001145:Arrhythmias, Cardiac / Q000151:congenital / Q000188:drug therapy; D004358:Drug Therapy / Q000379:methods* / Q000639:trends*; D005260:Female; D005315:Fetal Diseases / Q000188:drug therapy*; D046128:Fetal Therapies / Q000379:methods*; D006801:Humans; D008661:Metabolism, Inborn Errors / Q000188:drug therapy; D008954:Models, Biological; D006831:Polyhydramnios / Q000188:drug therapy; D011247:Pregnancy; D013971:Thyrotoxicosis / Q000151:congenital / Q000188:drug therapy